Target Price Review on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

In the most recent trading session, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares saw a move of +0.00%. Covering Wall Street analysts have a consensus target price of $62.93 on the stock. Target predictions might differ vastly from analyst to analyst. This target is applying estimates from analysts polled by Thomson Reuters. 

In order to arrive at a price target, analysts and investors alike use various metrics to determine where the stock might be headed. One of the most common is the Price to Earnings Ratio or P/E Ratio. This is calculated by taking the current share price and dividing it by the forecasted earnings per share. As of writing, Alnylam Pharmaceuticals, Inc. has a price to earnings ratio of N/A. Taking a step further, investors can also look to a firm’s price to earnings growth or PEG ratio. The PEG ratio represents the ratio of the price to earnings to the expected future growth rate of the company. A company with a PEG ratio greater than one might be considered overvalued using this metric alone. On the other hand if a firm has a PEG below one could be considered undervalued. A PEG that is close to one, is often considered fair value. The stock has a current PEG of -0.21.

Some other technicals to consider would be the moving averages of the company. In comparing the current price level of the equity to their moving averages, the shares are trading $7.48 off of the 50-day average of $40.21 and $-12.19 away from the 200-day moving average of $59.88.

Another important factor to consider when evaluating a stock’s current and future value are the 52 week high and low levels. As of the most recent bid at the time of writing, Alnylam Pharmaceuticals, Inc. shares are trading -56.29% away from the 52-week high mark of 109.10 and +51.98% off the 52-week bottom of 31.38.